PHARMACIST.io
PHARMACIST.io is a polypharmacy reference and training environment that analyzes complete medication regimens across nine modules, including drug-supplement interactions, cumulative adverse effects, therapeutic duplication, and renal/hepatic dosing. The platform draws on a three-layer evidence hierarchy—current Summaries of Product Characteristics, clinical guidelines, and expert consensus—with every finding tagged to its source for rapid verification. A pilot study of 1,077 real-world regimens found that 68.7% of polypharmacy patients had at least one previously unrecognized clinically significant medication-related problem.
- Healthcare Technology
- Digital Health
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Polypharmacy is increasingly common, yet medication review is complex and error-prone. Many patients take multiple prescriptions, OTC drugs, and supplements, creating risks of interactions, cumulative adverse effects, and dosing errors that clinicians may miss. A pilot study found that 68.7% of polypharmacy patients had at least one previously unrecognized clinically significant medication-related problem, and only 12% of patients 65+ had a problem-free medication list.
Solution
PHARMACIST.io provides a medication review engine that analyzes complete regimens across nine modules, covering drug-supplement interactions, cumulative adverse effects, therapeutic duplication, drug-food interactions, lifestyle interactions, perioperative safety, driving and psychomotor effects, renal and hepatic dosing, and pharmacogenomics. The platform draws on three layers of evidence: current Summaries of Product Characteristics as the regulatory base, Polish and international society clinical guidelines, and expert consensus where guidelines end. Every finding is tagged with its evidence layer so pharmacists can verify results in seconds. The engine is currently under multi-centre validation across cardiology, nephrology, internal medicine, emergency departments, hospital admissions, psychiatry, residential care homes, and community pharmacies.
Target Audience
Primary users are pharmacists, clinicians, and healthcare institutions managing polypharmacy patients, including hospital departments, residential care homes, and community pharmacies.
Features
- Nine-module medication review covering drug-supplement interactions, cumulative adverse effects, therapeutic duplication, drug-food interactions, lifestyle interactions, perioperative safety, driving and psychomotor effects, renal and hepatic dosing, and pharmacogenomics
- Three-layer evidence hierarchy: current SmPC as regulatory base, Polish and international society guidelines, and expert consensus for areas where guidelines end
- Every finding carries its evidence layer for rapid clinician verification
- PCNE V9.1, Beers AGS 2023, and STOPP/START criteria integrated into the analysis engine
- Upcoming modules include deprescribing, vaccines, hospital pharmacy, diagnostics, oncology, and metabolic pharmacotherapy
- Engine validated in a multi-centre research programme measuring agreement with expert assessment and acceptance by treating physicians